A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

  First | 1 2 3        [Sort alphabetically]   [Restore default list]

  Subjects -> PHARMACY AND PHARMACOLOGY (Total: 575 journals)
Showing 401 - 253 of 253 Journals sorted by number of followers
Pharmazeutische Zeitung     Full-text available via subscription   (Followers: 11)
Pharmazeutische Industrie     Full-text available via subscription   (Followers: 9)
Pharmaceutical Journal     Free   (Followers: 8)
Advanced Herbal Medicine     Open Access   (Followers: 8)
Pharmaceutical Fronts     Open Access   (Followers: 7)
Molekul     Open Access   (Followers: 7)
Advances in Pharmacology and Pharmacy     Open Access   (Followers: 6)
Drug Metabolism and Pharmacokinetics     Hybrid Journal   (Followers: 6)
AAPS Open     Open Access   (Followers: 5)
Journal of Drug Research in Ayurvedic Sciences     Open Access   (Followers: 4)
ACS Pharmacology & Translational Science     Hybrid Journal   (Followers: 4)
Advances in Traditional Medicine     Hybrid Journal   (Followers: 3)
Canadian Journal of Pain     Open Access   (Followers: 3)
PharmaNutrition     Hybrid Journal   (Followers: 3)
Journal of Drug Delivery Science and Technology     Hybrid Journal   (Followers: 3)
Journal of Herbal Science     Full-text available via subscription   (Followers: 3)
Journal of Pharmacological Sciences     Open Access   (Followers: 3)
Indian Journal of Drugs in Dermatology     Open Access   (Followers: 2)
British Journal of Pharmacy (BJPharm)     Open Access   (Followers: 2)
Current Research in Drug Discovery     Open Access   (Followers: 2)
Journal of Herbal Medicine     Hybrid Journal   (Followers: 2)
Asian Journal of Pharmaceutical Research and Health Care     Open Access   (Followers: 2)
Pharmacological Research - Modern Chinese Medicine     Open Access   (Followers: 2)
Archives of Pharmacy and Pharmaceutical Sciences     Open Access   (Followers: 2)
Current Issues in Pharmacy and Medical Sciences     Open Access   (Followers: 2)
International Journal of Immunopathology and Pharmacology     Open Access   (Followers: 2)
Advances in Pharmacoepidemiology & Drug Safety     Open Access   (Followers: 2)
European Journal of Medicinal Plants     Open Access   (Followers: 2)
Journal of Pharmaceutical Sciences and Pharmacology     Full-text available via subscription   (Followers: 2)
Journal of Education and Science     Open Access   (Followers: 2)
Drug Safety - Case Reports     Open Access   (Followers: 2)
Current Research in Pharmacology and Drug Discovery     Open Access   (Followers: 1)
Advances in Medical, Pharmaceutical and Dental Research     Open Access   (Followers: 1)
Pediatric Pharmacology     Open Access   (Followers: 1)
Journal of Metabolomics & Systems Biology     Open Access   (Followers: 1)
Regulatory Mechanisms in Biosystems     Open Access   (Followers: 1)
Integrative Medicine International     Open Access   (Followers: 1)
Journal of Applied Pharmaceutical Research     Open Access   (Followers: 1)
Herbal Medicines Journal     Open Access   (Followers: 1)
Farmakoèkonomika : Modern Pharmacoeconomic and Pharmacoepidemiology     Open Access   (Followers: 1)
Separation Science plus (SSC plus)     Hybrid Journal   (Followers: 1)
Advanced Therapeutics     Hybrid Journal   (Followers: 1)
Journal of Biopharmaceutics Sciences     Open Access   (Followers: 1)
Expert Review of Precision Medicine and Drug Development     Hybrid Journal   (Followers: 1)
Psychiatry and Clinical Psychopharmacology     Open Access   (Followers: 1)
Farmasains : Jurnal Ilmiah Ilmu Kefarmasian     Open Access   (Followers: 1)
Emerging Trends in Drugs, Addictions, and Health     Open Access   (Followers: 1)
Journal of Medicinal Plants for Economic Development     Open Access   (Followers: 1)
OpenNano     Open Access   (Followers: 1)
Safety and Risk of Pharmacotherapy     Open Access   (Followers: 1)
Journal of Pharmaceutical Technology, Research and Management     Open Access   (Followers: 1)
Journal of the American College of Clinical Pharmacy : JACCP     Hybrid Journal   (Followers: 1)
Open Pharmacoeconomics & Health Economics Journal     Open Access   (Followers: 1)
Pharmactuel     Open Access   (Followers: 1)
Al-Azhar Journal of Pharmaceutical Sciences     Open Access   (Followers: 1)
Chinese Herbal Medicines     Full-text available via subscription   (Followers: 1)
Drugs : Real World Outcomes     Hybrid Journal   (Followers: 1)
Pharmakon : Arzneimittel in Wissenschaft und Praxis     Full-text available via subscription   (Followers: 1)
Sustainable Chemistry and Pharmacy     Full-text available via subscription   (Followers: 1)
Medicines     Open Access   (Followers: 1)
Antiviral Chemistry and Chemotherapy     Open Access   (Followers: 1)
Future Journal of Pharmaceutical Sciences     Open Access   (Followers: 1)
Journal of Pharmaceutical Health Care and Sciences     Open Access   (Followers: 1)
East and Central African Journal of Pharmaceutical Sciences     Open Access   (Followers: 1)
Ethiopian Pharmaceutical Journal     Full-text available via subscription   (Followers: 1)
Pharmacy & Pharmacology     Open Access   (Followers: 1)
Clinical Complementary Medicine and Pharmacology     Open Access  
Exploratory Research in Clinical and Social Pharmacy     Open Access  
Indonesian Journal of Pharmaceutical Education     Open Access  
Future Drug Discovery     Open Access  
IUPHAR/BPS Guide to Pharmacology CITE     Open Access  
Journal of Applied Pharmaceutical Sciences and Research     Open Access  
Cephalalgia Reports     Open Access  
Pharmacon : Jurnal Farmasi Indonesia     Open Access  
Pharmacia     Open Access  
Research Results in Pharmacology     Open Access  
Journal of Toxins     Open Access  
Journal of Pharmaceutics & Pharmacology     Open Access  
Natural Product Communications     Open Access  
PharmaTutor     Open Access  
International Journal of Pharmaceutical Sciences and Developmental Research     Open Access  
Toxicological Research     Hybrid Journal  
Current Medical Science     Hybrid Journal  
EUREKA : Health Sciences     Open Access  
Iraqi Journal of Pharmacy     Open Access  
Revista Colombiana de Ciencias Químico-Farmacéuticas     Open Access  
Medicine in Drug Discovery     Open Access  
Frontiers in Medical Technology     Open Access  
International Journal of Medical and Pharmaceutical Case Reports     Open Access  
Asian Journal of Research in Medical and Pharmaceutical Sciences     Open Access  
Journal of Pharmaceutical Health Services Research     Hybrid Journal  
AboutOpen     Open Access  
Current Protocols in Pharmacology     Hybrid Journal  
Medical Cannabis and Cannabinoids     Open Access  
Ukrainian Biopharmaceutical Journal     Open Access  
Pharmaceutical Journal of Sri Lanka     Open Access  
Isan Journal of Pharmaceutical Sciences (IJPS)     Open Access  
Ciencia e Investigación     Open Access  
Jurnal Farmasi Sains dan Komunitas (Journal of Pharmaceutical Sciences and Community)     Open Access  
Toxicon : X     Open Access  
International Journal of Pharmaceutics: X     Open Access  
Jurnal Farmasi dan Ilmu Kefarmasian Indonesia     Open Access  
Open Pharmacology Journal     Open Access  
ExRNA     Open Access  
International Journal of Pharmaceutics & Pharmacology     Open Access  
Antibody Therapeutics     Open Access  
Journal of Faculty of Pharmacy of Ankara University     Open Access  
Iraqi Journal of Pharmaceutical Sciences     Open Access  
Journal of Medicinal Botany     Open Access  
Journal of Medicinal Herbs and Ethnomedicine     Open Access  
International Journal of Pharmacokinetics     Hybrid Journal  
Neuropsychopharmacology Reports     Open Access  
Reviews on Clinical Pharmacology and Drug Therapy     Full-text available via subscription  
SynOpen     Open Access  
Matrix Science Pharma     Open Access  
Contract Pharma     Full-text available via subscription  
Journal of Cellular Neuroscience and Oxidative Stress     Open Access  
Istanbul Journal of Pharmacy     Open Access  
Acta Pharmaceutica Indonesia     Open Access  
Indonesian Journal of Pharmacy     Open Access  
EMC - Cosmetologia Medica e Medicina degli Inestetismi Cutanei     Full-text available via subscription  
High-Throughput     Open Access  
Scientia Pharmaceutica     Open Access  
Trends in Peptide and Protein Sciences     Open Access  
Acta Physiologica Hungarica     Full-text available via subscription  
Jurnal Farmasi Sains dan Praktis     Open Access  
Jurnal Kefarmasian Indonesia     Open Access  
Pharmaceutical Historian     Open Access  
Planta Medica International Open     Open Access  
Archives of Razi Institute     Open Access  
Journal of Pharmaceutical Research     Open Access  
EJNMMI Radiopharmacy and Chemistry     Open Access  
FarmaJournal     Open Access  
Journal of Negative and No Positive Results     Open Access  
Pharmaciana     Open Access  
Folia Medica Indonesiana     Open Access  
Актуальні питання фармацевтичної та медичної науки та практики     Open Access  
International Journal of Pharmacology, Phytochemistry and Ethnomedicine     Open Access  
Фармацевтичний часопис     Open Access  
Ciência Equatorial     Open Access  
Iranian Journal of Pharmaceutical Research     Open Access  
Research & Reviews : A Journal of Drug Design & Discovery     Full-text available via subscription  
Asian Journal of Medical and Pharmaceutical Researches     Open Access  
Research & Reviews : A Journal of Pharmacognosy     Full-text available via subscription  
Ars Pharmaceutica     Open Access  
Pharmacognosy Communications     Partially Free  
Egyptian Pharmaceutical Journal     Open Access  
Pharmacological Reports     Hybrid Journal  
PZ Prisma : Materialien zur Fort- und Weiterbildung     Full-text available via subscription  
Chinese Journal of Pharmaceutical Analysis     Full-text available via subscription  
Journal of Nanopharmaceutics and Drug Delivery     Full-text available via subscription  
Journal of Hydrogels     Full-text available via subscription  
Manufacturing Chemist     Full-text available via subscription  
Pharmaceutica Analytica Acta     Open Access  
Journal of Pharmacovigilance     Open Access  
Current Pharmacology Reports     Hybrid Journal  
Nigerian Journal of Natural Products and Medicine     Full-text available via subscription  
International Journal of Herbs and Pharmacological Research     Open Access  
Bangladesh Journal of Physiology and Pharmacology     Open Access  
Research Journal of Pharmacognosy     Open Access  

  First | 1 2 3        [Sort alphabetically]   [Restore default list]

Similar Journals
Journal Cover
Antibody Therapeutics
Number of Followers: 0  

  This is an Open Access Journal Open Access journal
ISSN (Online) 2516-4236
Published by Oxford University Press Homepage  [424 journals]
  • A novel humanized Chi3l1 blocking antibody attenuates
           acetaminophen-induced liver injury in mice

    • Pages: 1 - 12
      Abstract: AbstractAcetaminophen (APAP) overdose is a leading cause of acute liver injury in the USA. The chitinase 3-like-1 (Chi3l1) protein contributes to APAP-induced liver injury (AILI) by promoting hepatic platelet recruitment. Here, we report the development of a Chi3l1-targeting antibody as a potential therapy for AILI. By immunizing a rabbit successively with the human and mouse Chi3l1 proteins, we isolated cross-reactive monoclonal antibodies (mAbs) from single memory B cells. One of the human and mouse Chi3l1 cross-reactive mAbs was humanized and characterized in both in vitro and in vivo biophysical and biological assays. X-ray crystallographic analysis of the lead antibody C59 in complex with the human Chi3l1 protein revealed that the kappa light contributes to majority of the antibody–antigen interaction; and that C59 binds to the 4α-5β loop and 4α-helix of Chi3l1, which is a functional epitope and hotspot for the development of Chi3l1 blocking antibodies. We humanized the C59 antibody by complementarity-determining region grafting and kappa chain framework region reverse mutations. The humanized C59 antibody exhibited similar efficacy as the parental rabbit antibody C59 in attenuating AILI in vivo. Our findings validate Chi3l1 as a potential drug target for AILI and provide proof of concept of developing Chi3l1 blocking antibody as a therapy for the treatment of AILI.
      PubDate: Mon, 07 Nov 2022 00:00:00 GMT
      DOI: 10.1093/abt/tbac027
      Issue No: Vol. 6, No. 1 (2022)
  • Developability assessment at early-stage discovery to enable development
           of antibody-derived therapeutics

    • Pages: 13 - 29
      Abstract: AbstractDevelopability refers to the likelihood that an antibody candidate will become a manufacturable, safe and efficacious drug. Although the safety and efficacy of a drug candidate will be well considered by sponsors and regulatory agencies, developability in the narrow sense can be defined as the likelihood that an antibody candidate will go smoothly through the chemistry, manufacturing and control (CMC) process at a reasonable cost and within a reasonable timeline. Developability in this sense is the focus of this review. To lower the risk that an antibody candidate with poor developability will move to the CMC stage, the candidate’s developability-related properties should be screened, assessed and optimized as early as possible. Assessment of developability at the early discovery stage should be performed in a rapid and high-throughput manner while consuming small amounts of testing materials. In addition to monoclonal antibodies, bispecific antibodies, multispecific antibodies and antibody-drug conjugates, as the derivatives of monoclonal antibodies, should also be assessed for developability. Moreover, we propose that the criterion of developability is relative: expected clinical indication, and the dosage and administration route of the antibody could affect this criterion. We also recommend a general screening process during the early discovery stage of antibody-derived therapeutics. With the advance of artificial intelligence-aided prediction of protein structures and features, computational tools can be used to predict, screen and optimize the developability of antibody candidates and greatly reduce the risk of moving a suboptimal candidate to the development stage.
      PubDate: Fri, 11 Nov 2022 00:00:00 GMT
      DOI: 10.1093/abt/tbac029
      Issue No: Vol. 6, No. 1 (2022)
  • Ceramic hydroxyapatite chromatography plays a critical role in bispecific
           antibody purification process for impurity removal

    • Pages: 30 - 37
      Abstract: AbstractBackgroundSignificant challenges exist in downstream purification of bispecific antibodies (BsAbs) due to the complexity of BsAb architecture. A unique panel of mispaired species can result in a higher level of product-related impurities. In addition to process-related impurities such as host cell proteins (HCPs) and residual DNA (resDNA), these product-related impurities must be separated from the targeted BsAb product to achieve high purity. Therefore, development of an efficient and robust chromatography purification process is essential to ensure the safety, quality, purity and efficacy of BsAb products that consequently meet regulatory requirements for clinical trials and commercialization.MethodsWe have developed a robust downstream BsAb process consisting of a mixed-mode ceramic hydroxyapatite (CHT) chromatography step, which offers unique separation capabilities tailored to BsAbs, and assessed impurity clearance.ResultsWe demonstrate that the CHT chromatography column provides additional clearance of low molecular weight (LMW) and high molecular weight (HMW) species that cannot be separated by other chromatography columns such as ion exchange for a particular BsAb, resulting in ≥98% CE-SDS (non-reduced) purity. Moreover, through Polysorbate-80 (PS-80) spiking and LC–MS HCP assessments, we reveal complete clearance of potential PS-80-degrading HCP populations in the CHT eluate product pool.ConclusionsIn summary, these results demonstrate that CHT mixed-mode chromatography plays an important role in separation of product- and process-related impurities in the BsAb downstream process.
      PubDate: Sat, 19 Nov 2022 00:00:00 GMT
      DOI: 10.1093/abt/tbac030
      Issue No: Vol. 6, No. 1 (2022)
  • Preclinical evaluation of IAP0971, a novel immunocytokine that binds
           specifically to PD1 and fuses IL15/IL15Rα complex

    • Pages: 38 - 48
      Abstract: AbstractBackgroundCurrently, cytokine therapy for cancer has demonstrated efficacy in certain diseases but is generally accompanied by severe toxicity. The field of antibody-cytokine fusion proteins (immunocytokines) arose to target these effector molecules to the tumor microenvironment to expand the therapeutic window of cytokine therapy. Therefore, we have developed a novel immunocytokine that binds specifically to programmed death 1 (PD1) and fuses IL15/IL15Rα complex (referred to as IAP0971) for cancer immunotherapy.MethodsWe report here the making of IAP0971, a novel immunocytokine that binds specifically to PD1 and fuses IL15/IL15Rα complex, and preclinical characterization including pharmacology, pharmacodynamics, pharmacokinetics and toxicology, and discuss its potential as a novel agent for treating patients with advanced malignant tumors.ResultsIAP0971 bound to human IL2/15Rβ proteins specifically and blocked PD1/PDL1 signaling transduction pathway. IAP0971 promoted the proliferation of CD8 + T cells and natural killer T (NKT) cells, and further activated NK cells to kill tumor cells validated by in vitro assays. In an hPD1 knock-in mouse model, IAP0971 showed potent anti-tumor activity. Preclinical studies in non-human primates following single or repeated dosing of IAP0971 showed favorable pharmacokinetics and well-tolerated toxicology profile.ConclusionIAP0971 has demonstrated a favorable safety profile and potent anti-tumor activities in vivo. A Phase I/IIa clinical trial to evaluate the safety, tolerability and preliminary efficacy of IAP0971 in patients with advanced malignant tumors is on-going (NCT05396391).
      PubDate: Thu, 17 Nov 2022 00:00:00 GMT
      DOI: 10.1093/abt/tbac031
      Issue No: Vol. 6, No. 1 (2022)
  • Comparative Assessment of the Binding and Neutralisation Activity of
           Bispecific Antibodies Against SARS-CoV-2 Variants

    • Pages: 49 - 58
      Abstract: AbstractBackgroundNeutralising antibodies against SARS-CoV-2 are a vital component in the fight against COVID-19 pandemic, having the potential of both therapeutic and prophylactic applications. Bispecific antibodies (BsAbs) against SARS-CoV-2 are particularly promising, given their ability to bind simultaneously to two distinct sites of the receptor-binding domain (RBD) of the viral spike protein. Such antibodies are complex molecules associated with multi-faceted mechanisms of action that require appropriate bioassays to ensure product quality and manufacturing consistency.MethodsWe developed procedures for biolayer interferometry (BLI) and a cell-based virus neutralisation assay, the focus reduction neutralisation test (FRNT). Using both assays, we tested a panel of five BsAbs against different spike variants (Ancestral, Delta and Omicron) to evaluate the use of these analytical methods in assessing binding and neutralisation activities of anti-SARS-CoV-2 therapeutics.ResultsWe found comparable trends between BLI-derived binding affinity and FRNT-based virus neutralisation activity. Antibodies that displayed high binding affinity against a variant were often followed by potent neutralisation at lower concentrations, whereas those with low binding affinity also demonstrated reduced neutralisation activity.ConclusionThe results support the utility of BLI and FRNT assays in measuring variant-specific binding and virus neutralisation activity of anti-SARS-CoV-2 antibodies.
      PubDate: Thu, 29 Dec 2022 00:00:00 GMT
      DOI: 10.1093/abt/tbac032
      Issue No: Vol. 6, No. 1 (2022)
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762

Your IP address:
Home (Search)
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-